Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Liabilities: 2019-2025

Historic Total Liabilities for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $55.0 million.

  • 4D Molecular Therapeutics' Total Liabilities rose 7.67% to $55.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.0 million, marking a year-over-year increase of 7.67%. This contributed to the annual value of $49.8 million for FY2024, which is 55.26% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Total Liabilities is $55.0 million, which was up 4.27% from $52.7 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Total Liabilities registered a high of $55.0 million during Q3 2025, and its lowest value of $14.3 million during Q2 2021.
  • Over the past 3 years, 4D Molecular Therapeutics' median Total Liabilities value was $32.1 million (recorded in 2023), while the average stood at $39.3 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 112.90% in 2022, then dropped by 11.97% in 2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Total Liabilities (Quarterly) stood at $34.4 million in 2021, then declined by 11.26% to $30.5 million in 2022, then climbed by 5.09% to $32.1 million in 2023, then spiked by 55.26% to $49.8 million in 2024, then increased by 7.67% to $55.0 million in 2025.
  • Its last three reported values are $55.0 million in Q3 2025, $52.7 million for Q2 2025, and $46.0 million during Q1 2025.